Strata Critical Medical (SRTA) Cash from Investing Activities (2019 - 2026)

Strata Critical Medical (SRTA) has 7 years of Cash from Investing Activities data on file, last reported at $24.7 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $24.7 million, up 21.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.1 million (up 1532.45% YoY), and the FY2025 annual result was $69.8 million, up 6965.16% from the prior year.
• Cash from Investing Activities climbed to $24.7 million in Q1 2026 per SRTA's latest filing, from $18.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $207.6 million in Q2 2022 and troughed at -$16.9 million in Q2 2024.
• A 5-year average of $21.9 million and a median of $11.0 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities soared 20849.06% in 2022, then sank 548.01% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $207.6 million in 2022, then tumbled by 99.96% to $75000.0 in 2023, then soared by 5201.33% to $4.0 million in 2024, then surged by 359.38% to $18.3 million in 2025, then surged by 35.39% to $24.7 million in 2026.
• Business Quant data shows SRTA's Cash from Investing Activities at $24.7 million in Q1 2026, $18.3 million in Q4 2025, and $2.4 million in Q3 2025.